New Drugs for Breast Cancer Treatment

Abstract

Breast cancer is the most common type of cancer in women, affecting approximately 12% of women over the course of their lifetime. It was estimated that there would be 81,550 new cases of invasive breast cancer in women in the United States (US), along with 49,290 new cases of non-invasive breast cancer. A search was conducted to find out the number of new breast cancer drugs that have been approved by US Food and Drug Administration (FDA) in the last 2 years (2020 2021), and the number of breast cancer drugs that are currently under Phase 3 clinical trials. Between 2020 and 2021, 4 new drugs have been approved by FDA for the treatment of breast cancer: Tukysa (Seagen), Margenza (MacroGenics), Phesgo (Genentech), and Trodelvy (Gilead Sciences). Research continues to find out new drugs that can help treat breast cancer. Currently, there are several breast cancer treatment drugs in Phase 3 clinical trials including two major new breast cancer drugs Palbociclib (Pfizer) and Ribociclib (Novartis). Pharmaceutical and biotech companies are making incredible contributions by developing many innovative and effective treatments for breast cancers. We are hopeful that many new breast cancer drugs will be approved in the coming years. Keywords: Breast cancer, Food and Drug Administration(FDA), New Drugs, Clinical Trials.